Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. (hereinafter referred to as “Xinyi Jinzhu”), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” (Notice Number: 2025B00891) issued by the State Drug Administration for famotidine injections. The drug passed the generic drug consistency evaluation.

Zhitongcaijing · 03/13 11:41
Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. (hereinafter referred to as “Xinyi Jinzhu”), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” (Notice Number: 2025B00891) issued by the State Drug Administration for famotidine injections. The drug passed the generic drug consistency evaluation.